Differences in the kinetics of spike peptide–induced IFN-γ and IL-2 detected in patients with IBD undergoing TNFi therapy suggest that this treatment might modify vaccine-induced spike-specific T cells. This evidence concerns the gene IL2 and inflammatory bowel disease.